CSPC Pharmaceutical Group (SEHK:1093) Expands AstraZeneca Ties, Is The Upside Already Priced In?

CSPC Pharmaceutical Group (SEHK:1093) is back in focus after a new collaboration, option and license agreement with AstraZeneca to develop siRNA based renal disease treatments using CSPC’s AI enabled nucleic acid drug platforms.

See our latest analysis for CSPC Pharmaceutical Group.

Those R&D updates and the AstraZeneca collaboration come as CSPC Pharmaceutical Group’s share price has climbed 15.10% over the past week, yet remains down 15.24% over three months. The 3 year total shareholder return of 42.59% points to stronger longer term momentum.

If you are interested in other healthcare stocks using AI in drug development, it could be a good time to review the 132 healthcare AI stocks

After a sharp 15.10% weekly jump but a weaker three month share price patch, the question with CSPC Pharmaceutical Group is whether that recent momentum already reflects the AstraZeneca deal and pipeline news, or if valuation still leaves room to wait.

Preferred P/E of 25x: Is it justified for CSPC Pharmaceutical Group?

On simple earnings metrics, CSPC Pharmaceutical Group trades on a P/E of 25x, which is roughly in line with its closest peers but considerably higher than the broader Hong Kong pharmaceuticals sector.

The P/E ratio compares the current share price to earnings per share, so a higher figure usually reflects higher growth expectations or a perceived quality premium. For CSPC Pharmaceutical Group, forecasts point to earnings growth of 14.5% per year, which is faster than the 12.9% expected for the Hong Kong market but below the 20% threshold often associated with high growth stories.

That gap shows up when comparing the current 25x P/E to the estimated fair P/E of 19.5x. This implies the market is paying more than the level the SWS model suggests could be reasonable over time. Against its own industry, the contrast is even stronger, because CSPC Pharmaceutical Group’s 25x P/E stands well above the Hong Kong pharmaceuticals average of 13.5x. This indicates investors are assigning the stock a much richer earnings multiple than sector peers and the level the fair ratio points to as a potential anchor.

Explore the SWS fair ratio for CSPC Pharmaceutical Group

Result: Price-to-earnings of 25x (OVERVALUED).

However, CSPC Pharmaceutical Group still faces risks if the AstraZeneca collaboration underdelivers, or if higher sector competition pressures both its revenue growth and P/E premium.

Find out about the key risks to this CSPC Pharmaceutical Group narrative.

Another View: SWS DCF model points to undervaluation

While the 25x P/E suggests CSPC Pharmaceutical Group trades on a rich earnings multiple, the SWS DCF model tells a different story. At a current price of HK$8.23 versus an estimated future cash flow value of HK$18.37, the stock is flagged as trading at a 55.2% discount.

That kind of gap between the earnings multiple and cash flow based estimate raises a simple question for investors: is the market overpaying on near term earnings, or underappreciating the longer term cash generation that the model is capturing?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CSPC Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 209 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

Next Steps

The mixed signals around CSPC Pharmaceutical Group make this a good moment to look past the headlines, review the full data set and decide where you stand. To see both sides of the story in one place, take a closer look at the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond CSPC Pharmaceutical Group?

If CSPC Pharmaceutical Group has caught your attention, do not stop there. Broaden your watchlist with other stocks that fit different return and risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com